Introduction
The number of patients receiving hematopoietic cell transplantation (HCT) has been steadily increasing in the last few years with a projected number of HCT survivors of 502,000 patients by 2030 [1] . This increase in utilization of HCT's has been accompanied with a significant improvement in longterm overall survival (OS) and a dramatic decrease in early transplant-related mortality [2] . OS after allogeneic HCT is dependent on multiple patient-related, transplant-related, and donor-related factors [3] . In the recent decades, several changes affected the outcomes of allogeneic HCT recipients including but not limited to better supportive care and graftversus host disease (GVHD) prevention measures, improved HLA matching and donor selection, increased usage of peripheral blood as a stem cell source, reduced intensity conditioning for older patients and the expansion of alternative donor transplantation, such as haploidentical and cord blood transplants [4] [5] [6] [7] . The national marrow donor program publishes survival outcomes from transplant centers focusing on the first year after allogeneic HCT. The first 12 months post allogeneic HCT carry a high risk of morbidity and mortality, as well as a high risk of disease relapse. It is estimated that the OS for patients receiving allogeneic HCT to be around This study was presented at ASH Annual meeting held in December 2016 at San Diego, CA.
65% at one year post transplantation [2] . Many centers use the publically available one year data to advise patients on transplant risks and OS. For patients who survive and are disease free 2 years post myeloablative (MAC) allogeneic HCT, the long-term survival is estimated to be at 85% with older age and GVHD being the principal risk factors for nonrelape death [8] . This survival has not changed significantly from a prior report by the Late Effects Working Committee for the Center of International Blood and Marrow Transplant Research (CIBMTR), which showed a long-term survival of 89% [9] . In the last few years, haploidentical transplantation with post-transplant cyclophosphamide has been introduced as an alternative donor source for patients lacking a suitably matched donor [10] . This new donor source in addition to more aggressive post-transplant consolidation strategies, such as use of hypomethylating agents, FLT-3 inhibitors, and tyrosine kinase inhibitors to prevent relapse have increased the pool of transplant survivors and may have an impact on long-term survival after the initial year post transplantation [11, 12] . The survival outcomes and the factors that affect these outcomes among allogeneic recipients who are alive and disease free at one year after HCT are of importance in the newer era of post-transplant consolidation and alternative donor sources. Moreover, as the one year survival data published by the national marrow donor program has significant variability among centers, center-specific long-term survival is also of importance to help identify causes of late mortality and areas of improvement within each center. The availability of such information will be helpful to council patients during their first anniversary visit and to identify the subgroup of survivors carrying a higher risk for later morbidity and mortality. In this report, we sought to determine long-term survival and evaluate risk factors for late mortality among patients who are alive and disease free at 1-year post allogeneic HCT.
Methods

Objective
The objective of this single institution retrospective analysis is to assess the long-term survival of allogeneic HCT recipients who are alive and disease free at one year post HCT. We also assessed for patient-related, disease-related, and transplant-related factors that are associated with late mortality after allogeneic HCT.
Study population
Six hundred and sixty-seven consecutive patients who underwent a first allogeneic HCT for hematologic malignancy between 2005 and 2016 at our center were included in this analysis. Fifty-four patients were excluded because their follow-up time was shorter than 1 year at time of analysis and 224 patients were excluded because of death or disease relapse in the first year post HCT. Three hundred and eighty-nine patients were included in the final analysis. The transplants were performed consecutively between January 2005 and June 2015. This time frame was chosen to allow a minimum of 12 months of post-transplant follow-up for surviving patients. HIDT was selected based on our center criteria that makes patients eligible for HIDT if there is no suitable MRD or MUD donor or such a donor is not available within an acceptable time frame. The patients underwent conditioning using a variety of preparative regimens and these were classified as MAC, reducedintensity (RICT) and non-myeloablative (NST) according to accepted criteria [13, 14] . All patients were transplanted in the outpatient setting including all conditioning intensities and donor sources with inpatient admissions reserved for complications necessitating such care.
Covariates
Patient-related, disease-related, and transplant-related variables were prospectively documented and obtained for this analysis from our comprehensive institutional database. Clinical factors examined in building the multivariate models on OS and late relapse included age, sex, race, year of transplant, diagnosis (acute myelogenous leukemia, myelodysplastic syndrome/myeloproliferative neoplasms/chronic myelogenous leukemia, acute lymphoblastic leukemia, non-Hodgkin lymphoma/Hodgkin lymphoma/chronic lymphocytic leukemia, or other malignancy), conditioning intensity (RICT/NST, MAC with total body irradiation, MAC without total body irradiation), donor type (MRDT, MUDT, HIDT), graft source (bone marrow or peripheral blood stem cells), HCT comorbidity index [15] , donor/recipient sex match, CIBMTR risk score, disease risk index (DRI) [16] , donor/ recipient CMV, and ABO group, need of immunosuppression at 1 year post HCT, and acute and chronic GVHD in the first year post HCT.
Endpoints
Outcomes analyzed were OS (time from transplantation to death), disease-free survival (DFS; survival without evidence of relapse of the underlying malignancy after transplantation), non-relapse mortality (NRM), relapse/ progression of malignancy, and chronic GVHD. Chronic GVHD was classified as mild, moderate, or severe by 2005 National Institutes of Health consensus criteria starting 2006 [17] . Chronic GVHD was prospectively evaluated, graded, and documented by a single practitioner within the program. All endpoints are reported beyond 1 year after HCT.
Statistical analysis
OS and disease-free survival were estimated by the Kaplan-Meier method. The cumulative incidences of NRM, relapse, acute, and chronic GVHD were calculated to accommodate competing risks. NRM and relapse are competing risks and combination of them defined DFS. Death without acute (or chronic) GVHD was the competing risk of acute (or chronic) GVHD. Log-log transformation was applied on survival and cumulative incidence probabilities to compute the 95% confidence intervals. Log-rank test and Gray's test were utilized to compare survival and cumulative incidence probabilities between subgroups, respectively. Cox proportional hazards models were developed for OS and relapse. The following covariates were considered in multivariate Cox analysis: age, race, sex, diagnosis, first BMT, donor type, conditioning intensity, cell source, DRI, CIBMTR risk category, HCT-CI, donor sex, donor CMV, recipient CMV, high-dose TBI, immunosuppression within 1 year, acute GVHD within 1 year (grade 2-4 and grade 3-4), chronic GVHD within 1 year, and year of transplantation. The factors were retained in the Cox model if their significance levels were less than 5%. The proportional hazards assumption was checked by temporarily including and testing time-dependent variables and the variables in the final models passed the proportionality test. The statistical analyses were performed using the software SAS (version 9.4, the SAS Institute, Cary, NC) and R package cmprsk (www.r-project.org).
Results
Patients characteristics
Six hundred and sixty-seven patients received a first allogeneic HCT between January of 2005 and January of 2015 at our center. Three hundred and eighty-nine patients (Table 1) were included in the analysis and met the inclusion criteria of having at least 1 year follow-up at time of analysis and being alive and without evidence of relapse within the first year. Any relapse before 1 year was an exclusion even if the patient was able to enter remission again and stay in remission for the 1-year evaluation. Donor source included HLA-matched related donor (MRDT, n = 142), 8 of 8 HLA-A, B, C and DRB1 allele matched volunteer unrelated donor (MUDT, n = 152) or T-replete haploidentical graft using post-transplant cyclophosphamide (HIDT, n = 95). The median age was 51 years (19-75) with a median follow up beyond 1 year for 
Survival estimates
The median OS at 1, 3, and 5 years after the first anniversary was 91% (95% CI 88-94%), 82% (95% CI 77-86%), and 78% (95% CI 72-82%) (Fig. 1) . DFS was 86% (95% CI 82-90%) and 74% (95% CI 68-79%) at 1 and 5 years after the first year post HCT. 7% (95% CI 4-9%) and 11% (95% CI 8-15%) of patients relapsed at 1 and 5 years beyond 1 year after HCT. NRM was 7% (95% CI 5-10%) and 15% (95% CI 11-20%) at 1 and 5 years after the first anniversary (Fig. 1) . The GVHD-free, relapse free survival (GRFS) defined as freedom from grade 3-4 acute GVHD, relapse and cGVHD requiring immunosuppression at 1 and 3 years was 43% (95% CI 38-48%) and 38 % (95% CI 33-43%). The most common reasons of all-cause mortality during the 5 years beyond year one were chronic GVHD, infections and late disease relapse.
Multivariate analysis on all-cause mortality
The multivariate analysis on late mortality for patients surviving at least one year without relapse after allogeneic HCT showed that male gender, need for immunosuppression at one year post HCT and being transplanted between 2005-2009 carried a higher risk of late mortality (Table 2) . Patients who had chronic GVHD requiring immunosuppression at 1-year post HCT had a mortality hazard ratio of 2.17 (95% CI (Fig. 2b) . No or mild chronic GVHD within one year exhibited protective effect for all-cause mortality in univariate analysis (Fig. 2c) . However, this effect turned out to be insignificant in multivariate analysis.
Multivariate analysis on relapse
The multivariate analysis on relapse beyond the first year after HCT is shown in Table 3 . Patients with high/very high DRI had a significant increase in late relapse compared to low risk patients (HR 26.40, 95% CI 3.51-198.6, p = 0.002). Patients who developed grade II-IV acute GVHD or chronic GVHD in the first year after transplant had lower risk of late relapse (HR 0.32 and 0.33 respectively, p-value < 0.05 for both) Fig. 3 . Developing grade I acute GVHD or mild chronic GVHD in the first year had no impact on late relapse compared to no acute or chronic GVHD.
Multivariate analysis on NRM
The cox model on NRM showed that male gender, patient age (>51 years at time of transplant), developing acute GVHD grade 3-4 in the first year and the need of immunosuppression at 1 year post transplantation are all factors predicting a higher risk of NRM beyond the first year of HCT (Table 4) . Patients receiving immunosuppression at 1 year post HCT had a significantly higher mortality compared to those not requiring immunosuppression (HR 4.42, CI 1.87-10.44, p < 0.001).
Discussion
This single center report of 389 HCT survivors after allogeneic HCT shows that patients who are alive and disease free at 1 year post HCT have an excellent long-term survival in concordance with prior reports from the Center for International Bone Marrow Transplant Research (CIBMTR) group [8, 9, 18] . The strength of this report in comparison to registry trials include consistency in supportive care measures among all patients, GVHD monitoring, and assessment of GVHD by a single dedicated nurse, complete access to detailed patient records for completeness of data and complete follow-up information on all patients. At our center, patients are routinely monitored very closely for at least 6 months post allogeneic HCT and for longer duration of time if any complications still require transplant center Survival after one year post allogeneic HCTexpertize beyond the 6 months period. All patients with chronic GVHD and are on immunosuppression continue to be cared for primarily by the transplant team rather than the referring oncologist. This analysis also reflects outcomes on a more recent group of patients where several transplant practices have been modified including better GVHD treatment and prevention, antimicrobial prophylaxis and a significantly lower rates of early transplant-related mortality. Late relapses remain a major cause of death among survivors of allogeneic HCT. Our analysis shows that patients with high/very high DRI remain at a significant risk of late death secondary to relapse compared to patients with low DRI. Relapse tended to remain a major factor in the first 3 years beyond year 1 and became very infrequent thereafter. These findings were consistent with a prior CIBMTR registry report [8] . This finding is of importance as early referral to transplantation can minimize disease risk in certain situations. Moreover, identifying the high risk patients and incorporating strategies to prevent relapse can potentially minimize a fatal complication. The Blood and Marrow Transplant Clinical Trial Network (BMTCTN) is looking into such strategies through multicenter trials. In a recent proposed study, patients with FLT3 positive AML will be randomized to a FLT3 inhibitor versus placebo for 2 years post transplantation in an effort to minimize relapse of such high risk group of patients. We have recently started using post-transplant FLT3 inhibitor (sorafenib), tyrosine kinase inhibitors, and post-transplant hypomethylating agents on high risk suitable candidates to minimize relapse risk [12, 19, 20] .
Unlike other registry reports, our analysis did not reveal that all severity of chronic GVHD impacts long-term survival, however, clinically significant chronic GVHD that requires systemic immunosuppression was a major risk factor for late overall and NRM. Getting chronic GVHD in the first year in our patient population does protect against late relapses, but if this cGVHD is severe enough to require systemic immunosuppression, the risks of immunosuppression outweigh the benefit of cGVHD leading to an overall increase in late mortality. Clearly, reduction of GVHD remains a priority of the transplant community with recent studies pioneered by BMTCTN looking at strategies to minimize that risk in two separate trials after reduced intensity (BMTCTN 1203) and myeloablative conditioning Years beyond 1 year after transplant shown that using post-transplant cyclophosphamide after Tcell replete haploidenitcal transplantation yields similar survival and significantly lower acute and chronic GVHD rates compared to MUD and MRD transplants using calcineurin inhibitors with MMF or methotrexate [21] [22] [23] . In our analysis, the choice of donor type (MRD, MUD and Haploidentical with post-transplant cyclophosphamide) had no impact on any of the survival results including OS, relapse, NRM, and DFS. This finding in an era where donor availability is near universal with the introduction of HIDT, patients who are alive and disease-free at one year post HCT will have an excellent long-term outcome irrespective of the donor choice.
As the HCT volumes continue to increase with a significant improvement in NRM, the population of HCT survivors (>100,000) is expected to increase five-fold by 2030 with 25% of patient ages ≥60 years [1] . Long-term care for HCT survivors will be challenging as many transplant centers lack the resources or long-term transplant clinics to follow up on these patients' specific healthcare needs and the optimal way to treat such patients [24] . The National Institute of Health (NIH) Late Effects Consensus Conference in June of 2016 identified several areas of research and practice recommendations aimed at improving survival and long-term outcomes of HCT survivors [25] . Several reports have been published from the involved working groups in this initiative including immune dysregulation and pathobiology [26] , healthcare delivery [27] , patient-centered outcomes [28] , subsequent neoplasms [29] , research methodology and study design [30] and cardiovascular disease and associated risk factors working group [31] . These recommendations will be the road map for centers to utilize with the hope to improve long-term quality and survival for patients surviving the first year after HCT (Table 5) .
This study addressed long-term survival in a recent cohort of transplant patients surviving the first year after allogeneic HCT. A major factor of HCT that is not addressed here is the long-term quality of life of such patients. We, among other, have published data on GVHDrelapse-free survival as a composite endpoint to measure quality of life [23, 32] showing that about one-third of patients seem to meet that endpoint at one year. This highlights the importance of recent NIH reports aiming at improving not only survival but also quality of care and quality of life.
In conclusion, patients who are alive and relapse free at one year post allogenic HCT enjoy excellent long-term survival. A small subset remain at risk of late relapse and mortality. Ongoing studies pioneered by the BMTCTN aiming at decreasing relapse and lowering GVHD, added to 
